Table 3.
Absence of PankoMabGEX ™ staining is an independent prognosticator for reduced 10-year survival
| 10-year survival | |||||
|---|---|---|---|---|---|
| 95% CI | |||||
| Covariate | Coefficient (b i ) | [HR Exp (b i )] | Lower | Upper | P-value |
| Histology (NST vs. other) | −0.94 | 0.39 | 0.09 | 1.71 | ns |
| Grading (G1. G2 vs. G3) | −0.39 | 0.68 | 0.19 | 2.47 | ns |
| pT (pT1 vs. pT2-pT4) | −0.03 | 0.97 | 0.34 | 2.80 | ns |
| pN (pN0 vs. pN1-pN3) | 0.68 | 1.98 | 0.64 | 6.11 | ns |
| CIS (fraction within the invasive carcinoma) (no vs. yes) | 0.05 | 1.05 | 0.39 | 2.85 | ns |
| ER (neg. vs. pos.) | −1.20 | 0.30 | 0.06 | 1.42 | ns |
| PR (neg. vs. pos.) | 0.26 | 1.30 | 0.37 | 4.62 | ns |
| Her2 (neg. vs. pos.) | 1.45 | 4.25 | 1.07 | 16.94 | 0.040 |
| age (≤55y vs. > 55 y.) | 0.74 | 2.09 | 0.69 | 6.31 | ns |
| PankoMabGEX™ double negative (no vs. yes) | 1.30 | 3.67 | 1.12 | 12.08 | 0.032 |